- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice
Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, while acknowledging both the opportunities and challenges that lie ahead in clinical practice.
EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis
EP: 2.Cost Drivers in Lupus Nephritis
EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making
EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches
EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources
EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results
EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis
EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment
EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice
Video content above is prompted by the following:
- What considerations (eg, individual patient characteristics, steroid use, drug interactions) guide your treatment choices for managing lupus nephritis?
- How important is multidisciplinary care in managing lupus nephritis, and how do you coordinate this?
- The ACR is working on a 2-part lupus guideline project expected next year. In what ways do you see these guidelines evolving in the future?
- What specific opportunities or challenges do you see on the horizon for managing lupus nephritis in practice?
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More
